Lundbeck bullish despite 1st-qtr sales and earnings declines

8 May 2019

Danish CNS specialist Lundbeck (LUND: CO) today announced first-quarter 2019 financials, showing that revenue reached 4,234 million Danish kroner ($634.8 million), representing a decline of 8% (6% in local currencies) compared to the same period last year. The decline was expected and a result of generic competition on Onfi (clobazam).

Core earnings before interest and tax (EBIT) reached 1,410 million kroner corresponding to a core EBIT margin of 33.3%. EBIT reached 1,200 million kroner in the quarter, down 27.5% compared to 1,656 million kroner in 2018 and the EBIT margin reached 28.3% compared to 36.1% the year before

Earnings per share (EPS) were 4.52 kroner compared to 6.03 kroner the year before, and missing average analysts’ expectations of 4.73 kroner, and core EPS declined 19% to 5.48 kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK